The treatment effect of omaveloxolone in halting progression, based on change in mFARS score, is particularly pronounced in individuals with Friedreich's ataxia who had disease onset at ≤15 years of age, suggests a post hoc subgroup analysis of MOXIe Part 2 presented at EAN 2024.